Prakt. lékáren. 2014; 10(2): 74-76

Possibilities of pharmaceutical care in patients with systemic sclerosis

Lucie Hromádková
Oddělení klinické farmacie, Nemocnice Na Homolce, Praha
Nemocniční lékárna, Masarykova nemocnice, Ústí nad Labem

Systemic sclerosis is a rare chronic connective tissue disease. Approach to the patient should be comprehensive and individualized

according to the clinical manifestation of the disease. Treatment options are still only symptomatic and are based on the European

League Against Rheumatism recommendations. Pharmacotherapy should be further encouraged with non-pharmacological and lifestyle

changes. The role of the pharmacist is especially in patient education, in identification and management of drug problems and

in increasing adherence to treatment.

Keywords: systemic sclerosis, therapy, rheumatic diseases

Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hromádková L. Possibilities of pharmaceutical care in patients with systemic sclerosis. Praktické lékárenství. 2014;10(2):74-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mayes MD. Epidemiology of systemic sclerosis and related diseases. Curr Opin Rheumatol 1997; 9: 557-561. Go to original source... Go to PubMed...
    2. Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8(4): R133. Go to original source... Go to PubMed...
    3. Chaudhary P, Chen X, Assassi S, et al. Cigarette smoking is not a risk factor for systemic sclerosis. Arthritis Rheum 2011; 63(10): 3098-3102. Go to original source... Go to PubMed...
    4. Hudson M, Lo E, Lu Y, et al. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 2011; 63(1): 230-238. Go to original source... Go to PubMed...
    5. Mayes MD, Ho KT. Understanding and managing scleroderma. Scleroderma foundation. [online] [cit. 2013-12-19]. Dostupný na WWW: <http://www.scleroderma.org/site/DocServer/UandM.pdf? docID =326>.
    6. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009; 48(Suppl 3): iii36-39. Go to original source... Go to PubMed...
    7. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a repot from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628. Go to original source... Go to PubMed...
    8. Hromadkova L, Soukup T, Cermakova E, Vlcek J. Drug compliance in patients with systemic scleroderma. Clin Rheumatol 2012; 31(11): 1577-1583. Go to original source... Go to PubMed...
    9. Hunzelmann N, Moinzadeh P, Ekkehard G, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009; 11: R30. Go to original source... Go to PubMed...
    10. Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009; 21: 636-641. Go to original source... Go to PubMed...
    11. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-1009. Go to original source... Go to PubMed...
    12. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 1841-1847. Go to original source...
    13. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Rayneud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998; 2: CD000953. Go to original source... Go to PubMed...
    14. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298: 561-564. Go to original source... Go to PubMed...
    15. Wigley FM, Seibold JF, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407-1414. Go to PubMed...
    16. Seibold JR, Denton CP, Furst DE, et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc). Arthritis Rheum 2005; 52: 4057.
    17. Channick RN, Simonneau G, Sitbon O, et al. Effect of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123. Go to original source... Go to PubMed...
    18. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000; 132: 425-493. Go to original source... Go to PubMed...
    19. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666. Go to original source... Go to PubMed...
    20. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970. Go to original source... Go to PubMed...
    21. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358. Go to original source...
    22. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.